United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Sells 34,360 Shares of Danaher Co. (NYSE:DHR)

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund lowered its position in shares of Danaher Co. (NYSE:DHR) by 22.8% in the third quarter, HoldingsChannel reports. The firm owned 116,176 shares of the conglomerate’s stock after selling 34,360 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Danaher were worth $32,299,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kovack Advisors Inc. grew its holdings in shares of Danaher by 3.4% during the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after purchasing an additional 41 shares during the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of Danaher by 0.5% during the third quarter. Oppenheimer & Co. Inc. now owns 25,120 shares of the conglomerate’s stock worth $6,984,000 after purchasing an additional 116 shares in the last quarter. Pinnacle Financial Partners Inc grew its stake in shares of Danaher by 1.2% during the third quarter. Pinnacle Financial Partners Inc now owns 61,130 shares of the conglomerate’s stock valued at $16,995,000 after purchasing an additional 706 shares during the last quarter. Simmons Bank increased its holdings in shares of Danaher by 3.5% in the third quarter. Simmons Bank now owns 25,966 shares of the conglomerate’s stock valued at $7,219,000 after purchasing an additional 883 shares in the last quarter. Finally, Haverford Trust Co raised its position in Danaher by 2.0% in the 3rd quarter. Haverford Trust Co now owns 14,732 shares of the conglomerate’s stock worth $4,096,000 after purchasing an additional 293 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on DHR. Wells Fargo & Company initiated coverage on Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. The Goldman Sachs Group upped their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Royal Bank of Canada dropped their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Leerink Partners raised their price target on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Stock Up 0.8 %

Shares of DHR stock opened at $241.47 on Thursday. The company has a market capitalization of $174.41 billion, a price-to-earnings ratio of 46.08, a P/E/G ratio of 4.40 and a beta of 0.85. Danaher Co. has a 12-month low of $200.36 and a 12-month high of $281.70. The firm has a fifty day moving average of $263.88 and a 200-day moving average of $260.77. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.02 earnings per share. As a group, equities research analysts predict that Danaher Co. will post 7.51 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is 20.61%.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.